About Datar Genetics
Datar Genetics is a Healthcare company based in Nashik (India) founded in 1992 by Rajan Datar. Liquid biopsy-based cancer diagnostic tests are provided. Datar Genetics has raised $2.98 million across 1 funding round from investors including Alkemi Partners. Datar Genetics was last valued at $77.53 million in August 2024. Its Indian entity Datar Cancer Genetics Private Limited reported revenue of ₹102 Cr. Datar Genetics offers products and services including Liquid Biopsy Tests and Circulating Tumor Cells Analysis. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
Datar Genetics was established in 1992 and is based in Nashik, India. Operations center on biotechnology for cancer diagnostics using liquid biopsy techniques. The product lineup consists of TruBlood for non-invasive malignancy detection, CellDx for tumor genome sequencing, Exacta for treatment personalization via tumor profiling, and ChemoScale for in-vitro evaluation of chemotherapy resistance. Focus remains on accessible, non-invasive testing in oncology.
- Headquarters Nashik, India
- Founders Rajan Datar
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website datarpgx.com
- Social LinkedIn Facebook
- Legal Name Datar Cancer Genetics
- Date of Incorporation 24 Jun, 1992
- Annual Revenue₹102 Cr
FY 2025 · +31% YoY
- Net Loss-₹3.85 Cr
FY 2025 · -4% margin
- EBITDA₹21.60 Cr
FY 2025 · 21% margin
- Total Equity Funding$2.98M (USD)
in 1 rounds
- Latest Funding Round$2.98M (USD), Angel Round
Aug 2024
- Investors
Associated legal entities of Datar Genetics
Datar Genetics operates through Datar Cancer Genetics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Datar Cancer Genetics Private Limited CIN U01110MH1992PTC067409 | Active | 24 Jun 1992 | Nashik, Maharashtra | ₹102 Cr | 4 | View details |
Products & Services of Datar Genetics
Datar Genetics offers a comprehensive portfolio of products and services, including Liquid Biopsy Tests and Circulating Tumor Cells Analysis.
Non-invasive blood tests for early cancer detection and monitoring.
Tests evaluating tumor cells in blood for cancer progression tracking.
Funding Insights of Datar Genetics
Datar Genetics has successfully raised a total of $2.98M through 1 strategic funding round. The most recent funding activity was a Angel Round of $2.98 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.98M
- Total Rounds 1
- Last Round Angel Round — $2.98M
- First Round $2.98M
(Aug 2024)
- Investors Count 1
All 1 funding rounds of Datar Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $2.98M | Angel Round | $77.53M | Alkemi Growth Capital | – |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2024 | $77.53M | •••••••• |
Last known valuation $77.53M (Aug 2024). 1 investors in total: 1 institutional.
Investors in Datar Genetics
Datar Genetics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Alkemi Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in early-stage healthcare companies for consumer well-being and growth. | 2017 | alkemivp.com | Delhi, India |
Investor details for Datar Genetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Datar Cancer Genetics Private Limited (Datar Genetics)
Datar Cancer Genetics Private Limited is the primary company behind Datar Genetics. The board of Datar Cancer Genetics Private Limited currently have 3 directors; the longest-serving is Sneha Rajan Datar, appointed in 2013. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sneha Rajan Datar DIN 01462203 | Director | 01 Apr 2013 | 13 yrs 7 mo | Datar Cancer Genetics Private Limited |
| Swati Satish Deshpande DIN 08312755 | Director | 23 Oct 2020 | 6 yrs | Datar Cancer Genetics Private Limited |
| Rajan Bhalchandra Datar DIN 01530860 | Director | 25 Mar 2022 | 4 yrs 7 mo | Datar Cancer Genetics Private Limited |
People of Datar Genetics
16 people are tracked at Datar Genetics (9 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Girish Dc | Divisional Business Head | Leadership |
Atreyee Saha | CEO | Leadership |
Dr. Darshana Patil | Senior Director - Global Strategy And Medical Affairs | Leadership |
Stefan Schuster | Managing Director Europe | Leadership |
Manjiri Shaikh | General Manager | Leadership |
Tim Courtemarche | Area Sales Director | Leadership |
Praveen Bharamagoudar | Chief Business Officer - India & SE Asia | Leadership |
| Director ( Operations) | Leadership | |
Arun Nile | Sr. Scientist | Team |
Akshay Ainwale | Scientist | Team |
Pooja Aher | Junior Scientist | Team |
Parijat Gaikwad | Manager Business Development | Team |
Dershna Lad | UK Oncology Product Specialist - Datar Cancer Genetics | Team |
Chad Bonfiglio | Business Development Manager | Team |
Andreea Dobocan | Scientist | Team |
Complete people profiles for Datar Genetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Datar Genetics
Figures of Datar Cancer Genetics Private Limited, the primary company behind Datar Genetics, for FY 2025. Revenue was ₹102 Cr (+31% year on year). Net loss was -₹3.85 Cr (-4% margin). EBITDA was ₹21.60 Cr (21% margin). Revenue has grown at a compounded annual rate of +16% over three years and +51% over five years.
- ₹102 CrRevenue · FY 2025 · +31% YoY
- -₹3.85 CrNet loss · -4% margin
- ₹21.60 CrEBITDA · 21% margin
- ₹120 CrPaid-up capital
- +16%Revenue CAGR, 3 years
- +51%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Datar Cancer Genetics Private Limited are on its company page.
Detailed financial statements for Datar Genetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Datar Genetics
3 dated milestones of Datar Genetics across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Datar Genetics is founded.
- Funding First funding round of $3.0M.
- Milestone Reaches Minicorn status.
Web traffic of Datar Genetics
The website of Datar Genetics (datarpgx.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 67.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Datar Genetics
Complete news archive for Datar Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Datar Genetics
Datar Genetics was founded in 1992 and raised its 1st funding round 32 years after it was founded.
Datar Genetics is headquartered in Nashik, India. It is registered at Nashik, Maharashtra, India.
Datar Genetics is a funded company, having raised a total of $2.98M across 1 funding round to date. The company's 1st funding round was a Angel Round of $2.98M, raised on Aug 2024.
The primary company behind Datar Genetics, Datar Cancer Genetics Private Limited, reported revenue of ₹102 Cr for FY 2025, up 31% year on year.
Datar Genetics was established in 1992 and is based in Nashik, India. Operations center on biotechnology for cancer diagnostics using liquid biopsy techniques. The product lineup consists of TruBlood for non-invasive malignancy detection, CellDx for tumor genome sequencing, Exacta for treatment personalization via tumor profiling, and ChemoScale for in-vitro evaluation of chemotherapy resistance. Focus remains on accessible, non-invasive testing in oncology.
Datar Genetics offers Liquid Biopsy Tests and Circulating Tumor Cells Analysis.
Datar Genetics has 1 investor. Key investors include Alkemi Partners.
The valuation of Datar Genetics is $77.53M as of Aug 2024.
Datar Genetics operates through Datar Cancer Genetics Private Limited.
The legal entities of Datar Genetics currently have 4 directors, including Sneha Rajan Datar, Swati Satish Deshpande, Rajan Bhalchandra Datar and others.